Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

Friedrich Stölzel, MD, David M. Poitz, PhD, Laleh S. Arabanian, Jens Friedrichs, PhD, Denitsa Docheva, PhD, Matthias Schieker, MD, Fernando A. Fierro, PhD, Uwe Platzbecker, MD, Ruth H. Strasser, MD, Martin Bornhäuser, MD, Carsten Werner, PhD, Gerhard Ehninger, Thomas Illmer, MD

Blood (2012) 120 (21): 3459.

https://doi.org/10.1182/blood.V120.21.3459.3459

Published: 2012

Journal Articles

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Friedrich Stölzel, MD, Michael Kramer, Brigitte Mohr, PhD, Martin Wermke, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 1715.

https://doi.org/10.1182/blood.V120.21.1715.1715

Published: 2012

Journal Articles

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Stefani Parmentier, MD, Michael Kramer, Katharina Koch, Brigitte Mohr, PhD, Christian Klesse, Christian Thiede, Christoph Röllig, Mathias Hänel, MD, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, Walter E. Aulitzky, Wolfgang E. Berdel, MD, Hubert Serve, Prof. Dr. med., Stefan W. Krause, Jiri Mayer, MD, Martin Bornhäuser, MD, Gerhard Ehninger, Markus Schaich, MD

Blood (2012) 120 (21): 1481.

https://doi.org/10.1182/blood.V120.21.1481.1481

Published: 2012

Journal Articles

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Blood (2012) 120 (21): 144.

https://doi.org/10.1182/blood.V120.21.144.144

Published: 2012

Journal Articles

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Jan Moritz Middeke, MD, Stefani Parmentier, MD, Nael Alakel, MD, Markus Schaich, MD, Christian Thiede, Uwe Platzbecker, MD, Christoph Röllig, Mathias Hänel, MD, Gernot Stuhler, MD, Anke Morgner, MD, Uta Eulenstein, Gerhard Ehninger, Martin Bornhäuser, MD, Johannes Schetelig, MD

Blood (2012) 120 (21): 2017.

https://doi.org/10.1182/blood.V120.21.2017.2017

Published: 2012

Journal Articles

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Sebastian Tuve, MD, Felix Bahr, Rebekka Wehner, PhD, Uwe Platzbecker, MD, Martin Wermke, MD, Nona Shayegi, MD, Jan Moritz Middeke, MD, Christoph Röllig, Johannes Schetelig, Gerhard Ehninger, Marc Schmitz, MD, Martin Bornhäuser, MD

Blood (2012) 120 (21): 4167.

https://doi.org/10.1182/blood.V120.21.4167.4167

Published: 2012

Journal Articles

Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation

Katja Sockel, MD, Claudia Schönefeldt, MSc, Sieghart Sopper, Martin Wermke, MD, Marc Schmitz, MD, Gerhard Ehninger, Martin Bornhäuser, MD, Dominik Wolf, MD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 4122.

https://doi.org/10.1182/blood.V120.21.4122.4122

Published: 2012

Journal Articles

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Blood (2012) 120 (21): 229.

https://doi.org/10.1182/blood.V120.21.229.229

Published: 2012

Journal Articles

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

Uwe Platzbecker, MD, Friederike Braulke, Andrea Kuendgen, Katharina S. Götze, Gesine Bug, Katayoon Shirneshan, Christoph Röllig, Martin Bornhäuser, MD, Ralph Naumann, MD, Jürgen Neesen, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, Gerhard Ehninger, Prof., Ulrich Germing, MD, Detlef Haase, Martin Wermke, MD

Blood (2012) 120 (21): 921.

https://doi.org/10.1182/blood.V120.21.921.921

Published: 2012

Journal Articles

A Unique Case of a Donor Cell Acute Myeloid Leukemia Reveals Complex Kinetics of Mutations and Evolution of the Disease

Sylvia Herold, PhD, Matthias Kuhn, Uwe Platzbecker, MD, Stange Thoralf, Jörgen Radke, MD, Caroline Heiderich, Lange Thoralf, MD, Kerstin Gutsche, MD, Johannes Schetelig, Stefani Parmentier, MD, Brigitte Mohr, PhD, Markus Schaich, MD, Hubert Serve, Prof. Dr. med., Christian H. Brandts, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede

Blood (2012) 120 (21): 886.

https://doi.org/10.1182/blood.V120.21.886.886

Published: 2012

Journal Articles

Redirection of Immune Effector Cells by Bispecific Antibody Systems for the Treatment of Acute Myeloid Leukemia

Claudia Arndt, Anja Feldmann, Stefanie Koristka, Irene Michalk, Marc Cartellieri, Slava Stamova, Malte von Bonin, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Michael Bachmann

Blood (2011) 118 (21): 1528.

https://doi.org/10.1182/blood.V118.21.1528.1528

Published: 2011

Journal Articles

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Christian Thiede, MD, Nona Shayegi, MD, Michael Kramer, Martin Bornhäuser, MD, Markus Schaich, MD, Johannes Schetelig, MD, Uwe Platzbecker, MD, Christoph Röllig, MD, Gerhard Ehninger, MD

Blood (2011) 118 (21): 1445.

https://doi.org/10.1182/blood.V118.21.1445.1445

Published: 2011

Journal Articles

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

Uwe Platzbecker, MD, Ulrich Schuler, Martin Bornhäuser, Michael Kramer, Markus Schaich, MD, Uta Oelschlagel, Brigitte Mohr, Mathias Hänel, Hannes Wandt, Thomas Wagner, Hermann Einsele, Stefan W. Krause, MD, Heinrich Bodenstein, Walter E. Aulitzky, Norbert Schmitz, Anthony D. Ho, Gerhard Ehninger, MD, Christoph Röllig, MD

Blood (2011) 118 (21): 765.

https://doi.org/10.1182/blood.V118.21.765.765

Published: 2011

Journal Articles

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Friedrich Stöolzel, MD, Thomas Illmer, MD, Claudia Dill, Michael Kramer, Brigitte Mohr, Christian Thiede, MD, Uwe Platzbecker, MD, Johannes Schetelig, MD, Christoph Röllig, MD, Martin Bornhäuser, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2011) 118 (21): 935.

https://doi.org/10.1182/blood.V118.21.935.935

Published: 2011

Journal Articles

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia

Marc Cartellieri, Irene Michalk, Malte von Bonin, Thomas Krüger, Slava Stamova, Stefanie Koristka, Claudia Arndt, Anja Feldmann, Marc Schmitz, Martin Wermke, MD, Dirk Lindemann, Martin Bornhäuser, Gerhard Ehninger, MD, Michael Bachmann

Blood (2011) 118 (21): 2618.

https://doi.org/10.1182/blood.V118.21.2618.2618

Published: 2011

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Blood (2011) 118 (21): 247.

https://doi.org/10.1182/blood.V118.21.247.247

Published: 2011

Journal Articles

Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies,

Stefanie Koristka, Marc Cartellieri, Anke Theil, Claudia Arndt, Anja Feldmann, Irene Michalk, Marc Schmitz, Karsten Kretschmer, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Michael Bachmann

Blood (2011) 118 (21): 4041.

https://doi.org/10.1182/blood.V118.21.4041.4041

Published: 2011

Journal Articles

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Blood (2011) 118 (21): 1019.

https://doi.org/10.1182/blood.V118.21.1019.1019

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 493.

https://doi.org/10.1182/blood.V118.21.493.493

Published: 2011

NARROW

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia

Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL)

Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial

Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory AML – Interim Results of the Bridge Trial

Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation

Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes

A Unique Case of a Donor Cell Acute Myeloid Leukemia Reveals Complex Kinetics of Mutations and Evolution of the Disease

Redirection of Immune Effector Cells by Bispecific Antibody Systems for the Treatment of Acute Myeloid Leukemia

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies,

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only